vs
Side-by-side financial comparison of Celularity Inc (CELU) and Digimarc CORP (DMRC). Click either name above to swap in a different company.
Digimarc CORP is the larger business by last-quarter revenue ($8.9M vs $5.3M, roughly 1.7× Celularity Inc). Digimarc CORP runs the higher net margin — -47.2% vs -436.7%, a 389.5% gap on every dollar of revenue. On growth, Digimarc CORP posted the faster year-over-year revenue change (2.9% vs -43.2%). Over the past eight quarters, Digimarc CORP's revenue compounded faster (-5.3% CAGR vs -33.9%).
Celularity Inc is a clinical-stage biotechnology firm that develops off-the-shelf placental-derived cell therapies and immunotherapies for treating cancer, autoimmune, and degenerative diseases. It operates primarily in the U.S. market, with product candidates covering oncology, regenerative medicine, and infectious disease segments.
Digimarc Corporation is a provider of enterprise software and services. The company's software, which includes digital identifiers, is designed to address counterfeiting, product authenticity, recycling accuracy, and supply chain traceability. Digimarc products are created for multiple industries such as apparel, consumer packaged goods, health and beauty, and automotive.
CELU vs DMRC — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $5.3M | $8.9M |
| Net Profit | $-23.1M | $-4.2M |
| Gross Margin | 26.1% | 63.5% |
| Operating Margin | -244.1% | -48.2% |
| Net Margin | -436.7% | -47.2% |
| Revenue YoY | -43.2% | 2.9% |
| Net Profit YoY | -43.3% | 51.4% |
| EPS (diluted) | $-0.88 | $-0.18 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $8.9M | ||
| Q3 25 | $5.3M | $7.6M | ||
| Q2 25 | $5.7M | $8.0M | ||
| Q1 25 | $11.4M | $9.4M | ||
| Q4 24 | $18.1M | $8.7M | ||
| Q3 24 | $9.3M | $9.4M | ||
| Q2 24 | $12.1M | $10.4M | ||
| Q1 24 | $14.7M | $9.9M |
| Q4 25 | — | $-4.2M | ||
| Q3 25 | $-23.1M | $-8.2M | ||
| Q2 25 | $-24.5M | $-8.2M | ||
| Q1 25 | $-19.8M | $-11.7M | ||
| Q4 24 | $-13.3M | $-8.6M | ||
| Q3 24 | $-16.1M | $-10.8M | ||
| Q2 24 | $-6.5M | $-9.3M | ||
| Q1 24 | $-22.0M | $-10.3M |
| Q4 25 | — | 63.5% | ||
| Q3 25 | 26.1% | 58.3% | ||
| Q2 25 | 8.6% | 58.8% | ||
| Q1 25 | 68.9% | 65.0% | ||
| Q4 24 | 59.5% | 60.8% | ||
| Q3 24 | 58.2% | 62.4% | ||
| Q2 24 | 82.5% | 66.1% | ||
| Q1 24 | 88.8% | 62.5% |
| Q4 25 | — | -48.2% | ||
| Q3 25 | -244.1% | -109.7% | ||
| Q2 25 | -276.6% | -105.2% | ||
| Q1 25 | -91.8% | -128.9% | ||
| Q4 24 | -51.2% | -105.1% | ||
| Q3 24 | -124.0% | -120.4% | ||
| Q2 24 | -84.0% | -96.2% | ||
| Q1 24 | -50.2% | -109.2% |
| Q4 25 | — | -47.2% | ||
| Q3 25 | -436.7% | -106.9% | ||
| Q2 25 | -427.5% | -102.6% | ||
| Q1 25 | -172.9% | -125.2% | ||
| Q4 24 | -73.3% | -99.9% | ||
| Q3 24 | -173.2% | -113.9% | ||
| Q2 24 | -53.6% | -89.3% | ||
| Q1 24 | -149.9% | -104.0% |
| Q4 25 | — | $-0.18 | ||
| Q3 25 | $-0.88 | $-0.38 | ||
| Q2 25 | $-1.02 | $-0.38 | ||
| Q1 25 | $-0.84 | $-0.55 | ||
| Q4 24 | $-0.58 | $-0.40 | ||
| Q3 24 | $-0.73 | $-0.50 | ||
| Q2 24 | $-0.30 | $-0.43 | ||
| Q1 24 | $-1.03 | $-0.50 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $120.0K | $12.9M |
| Total DebtLower is stronger | $35.7M | — |
| Stockholders' EquityBook value | $-20.1M | $40.2M |
| Total Assets | $114.2M | $53.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $12.9M | ||
| Q3 25 | $120.0K | $12.6M | ||
| Q2 25 | $863.0K | $16.1M | ||
| Q1 25 | $293.0K | $21.6M | ||
| Q4 24 | $738.0K | $28.7M | ||
| Q3 24 | $133.0K | $33.7M | ||
| Q2 24 | $467.0K | $41.5M | ||
| Q1 24 | $1.9M | $48.9M |
| Q4 25 | — | — | ||
| Q3 25 | $35.7M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $40.2M | ||
| Q3 25 | $-20.1M | $41.4M | ||
| Q2 25 | $-25.5M | $46.5M | ||
| Q1 25 | $-5.5M | $50.0M | ||
| Q4 24 | $8.8M | $61.4M | ||
| Q3 24 | $17.3M | $70.2M | ||
| Q2 24 | $27.8M | $77.2M | ||
| Q1 24 | $31.2M | $84.5M |
| Q4 25 | — | $53.0M | ||
| Q3 25 | $114.2M | $55.4M | ||
| Q2 25 | $120.3M | $60.7M | ||
| Q1 25 | $128.9M | $66.5M | ||
| Q4 24 | $132.7M | $75.8M | ||
| Q3 24 | $128.8M | $85.0M | ||
| Q2 24 | $135.5M | $93.4M | ||
| Q1 24 | $143.8M | $99.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-4.2M | $991.0K |
| Free Cash FlowOCF − Capex | — | $895.0K |
| FCF MarginFCF / Revenue | — | 10.0% |
| Capex IntensityCapex / Revenue | — | 1.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-12.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $991.0K | ||
| Q3 25 | $-4.2M | $-2.6M | ||
| Q2 25 | $-999.0K | $-4.7M | ||
| Q1 25 | $-3.0M | $-5.5M | ||
| Q4 24 | $1.6M | $-4.2M | ||
| Q3 24 | $-144.0K | $-7.1M | ||
| Q2 24 | $-3.4M | $-6.8M | ||
| Q1 24 | $-4.4M | $-8.4M |
| Q4 25 | — | $895.0K | ||
| Q3 25 | — | $-2.8M | ||
| Q2 25 | — | $-4.9M | ||
| Q1 25 | — | $-5.5M | ||
| Q4 24 | $1.5M | $-4.2M | ||
| Q3 24 | — | $-7.2M | ||
| Q2 24 | $-3.5M | $-6.9M | ||
| Q1 24 | $-4.4M | $-8.5M |
| Q4 25 | — | 10.0% | ||
| Q3 25 | — | -36.9% | ||
| Q2 25 | — | -61.0% | ||
| Q1 25 | — | -59.1% | ||
| Q4 24 | 8.3% | -49.1% | ||
| Q3 24 | — | -75.7% | ||
| Q2 24 | -28.7% | -66.1% | ||
| Q1 24 | -30.3% | -85.8% |
| Q4 25 | — | 1.1% | ||
| Q3 25 | — | 2.9% | ||
| Q2 25 | — | 2.5% | ||
| Q1 25 | — | 0.6% | ||
| Q4 24 | 0.5% | 0.2% | ||
| Q3 24 | 0.0% | 0.7% | ||
| Q2 24 | 0.3% | 0.3% | ||
| Q1 24 | 0.3% | 1.1% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CELU
| License Royalty And Other | $2.9M | 56% |
| Degenerative Disease | $2.2M | 42% |
DMRC
| Subscription | $5.3M | 60% |
| The Government | $3.6M | 41% |
